Contact Us

Modality: Antibodies and Bispecifics

How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery

At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]

How Our Mytide Investment Supports the Peptides Ecosystem

Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]

Partnering with Target-Rich Biotech Companies

Running a successful early-stage biotech company requires a careful balance of enterprise and discipline. Companies must develop disruptive new discovery technologies or insights into disease biology that can have broad applications, but they must choose their first disease application(s) carefully. This tension is in large part driven by the demands around financing a startup biotech […]

Democratizing Access for Academic Entrepreneurs

We are advancing Alloy as a biotechnology ecosystem company, because we believe strongly that the innovation and breakthroughs that result from a network of relationships are far more powerful than those that can advance from silos. We collaborate with everyone to compete against disease. An exciting element of this dynamic is how under-resourced, smaller teams […]

Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning

Biotech ecosystem company Alloy Therapeutics leads the round, joined by Uncommon Denominator and Mytide founders BOSTON, March 8th, 2021–Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing. The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon […]

Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery platform and services for its ecosystem of 100+ global partners Boston, MA, USA and Basel, Switzerland, December 9th, 2021 – Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and […]

Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics

Wheeler Bio is a biomanufacturing company co-founded by Alloy Therapeutics and Echo Investment Capital to accelerate antibody therapeutics from discovery to IND. Operating out of Oklahoma City and Boston, Wheeler integrates cGMP manufacturing with Alloy’s discovery ecosystem to provide emerging biopharma companies a predictable, high-speed path to clinical trials. BOSTON, MA & OKLAHOMA CITY, OK, […]

Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing

Seed Financing Will Scale Company’s Technology and Business Operations to Serve Clients of All Stages Vernal Biosciences launched with seed financing led by Alloy Therapeutics to democratize access to high-purity mRNA manufacturing for research and clinical-stage programs. Led by mRNA veteran Christian Cobaugh, Vernal provides a scalable manufacturing platform within the Alloy biotechnology ecosystem to […]

Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases

Alloy Therapeutics and Pyxis Oncology launched Voxall Therapeutics, a joint venture focused on developing novel immune-modulating antibody therapies for cancer and autoimmune diseases. The collaboration integrates Alloy’s ATX-Gx™ discovery platform with Pyxis’ target expertise and preclinical capabilities, facilitated by Alloy’s 82VS venture studio. LEXINGTON & CAMBRIDGE, Mass., May 25th, 2021 – Alloy Therapeutics (“Alloy”) and […]